Patents by Inventor Shekhar Viswanath
Shekhar Viswanath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120028908Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.Type: ApplicationFiled: October 1, 2011Publication date: February 2, 2012Applicant: Abbott LaboratoriesInventors: Shekhar VISWANATH, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
-
Patent number: 8034926Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.Type: GrantFiled: September 20, 2010Date of Patent: October 11, 2011Assignee: Abbott LaboratoriesInventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
-
Patent number: 8030326Abstract: Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate.Type: GrantFiled: September 20, 2010Date of Patent: October 4, 2011Assignee: Abbott LaboratoriesInventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
-
Publication number: 20110009325Abstract: Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate.Type: ApplicationFiled: September 20, 2010Publication date: January 13, 2011Applicant: Abbott LaboratoriesInventors: SHEKHAR VISWANATH, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
-
Publication number: 20110009618Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.Type: ApplicationFiled: September 20, 2010Publication date: January 13, 2011Applicant: Abbott LaboratoriesInventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
-
Patent number: 7820812Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.Type: GrantFiled: July 23, 2007Date of Patent: October 26, 2010Assignee: Abbott LaboratoriesInventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
-
Patent number: 7812032Abstract: A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate.Type: GrantFiled: July 23, 2007Date of Patent: October 12, 2010Assignee: Abbott LaboratoriesInventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
-
Publication number: 20080091008Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.Type: ApplicationFiled: July 23, 2007Publication date: April 17, 2008Applicant: ABBOTT LABORATORIESInventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
-
Publication number: 20080085880Abstract: A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate.Type: ApplicationFiled: July 23, 2007Publication date: April 10, 2008Applicant: ABBOTT LABORATORIESInventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
-
Patent number: 7057049Abstract: This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers. The substituted pyrazoles correspond in structure to Formula (I): wherein R3A, R3B, R3C, Y1, Y2, Y3, Y4, and Y5 are as defined in the specification.Type: GrantFiled: April 1, 2003Date of Patent: June 6, 2006Assignee: Pharmacia CorporationInventors: Kimberley C. Allen, Dennis K. Anderson, John E. Baldus, Todd Boehlow, Jerry D. Clark, Dan R. Dukesherer, Albert D. Edney, Tom Fevig, Sastry Kunda, Jon P. Lawson, Patrick H. Lau, Lisa L. McDermott, Michael K. Mao, Jodi L. Moe, Partha Mudipalli, Win Naing, Shaun R. Selness, Christine B. Seymour, Tobin C. Schilke, Shekhar Viswanath, John K. Walker, Gopichand Yalamanchili
-
Patent number: 6897318Abstract: This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers. The substituted pyrazoles correspond in structure to Formula (I): wherein R3A, R3B, R3C, Y1, Y2, Y3, Y4, and Y5 are as defined in the specification.Type: GrantFiled: September 25, 2002Date of Patent: May 24, 2005Assignee: Pharmacia CorporationInventors: Kimberly K. Allen, Dennis K. Anderson, John E. Baldus, Jerry D. Clark, Albert D. Edeny, Patrick H. Lau, Daniel R. Dukesherer, Lisa McDermott, Michael K. Mao, Gopi Yalamanchili, Jodi L. Moe, Partha Mudipalli, Win Naing, Shaun R. Selness, Christine Seymour, Shekhar Viswanath, John K. Walker
-
Publication number: 20030225108Abstract: This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers.Type: ApplicationFiled: April 1, 2003Publication date: December 4, 2003Inventors: Kimberley C. Allen, Dennis K. Anderson, John E. Baldus, Todd Boehlow, Jerry D. Clark, Daniel R. Dukesherer, Albert D. Edney, Tom Fevig, Sastry Kundra, Jon P. Lawson, Patrick H. Lau, Lisa L. McDermott, Michael K. Mao, Jodi L. Moe, Partha Mudipalli, Win Naing, Shaun R. Selness, Christine B. Seymour, Tobin C. Schilke, Shekhar Viswanath, John K. Walker, Gopichand Yalamanchili
-
Publication number: 20030144302Abstract: This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers.Type: ApplicationFiled: September 25, 2002Publication date: July 31, 2003Inventors: Kimberly K. Allen, Dennis K. Anderson, John E. Baldus, Jerry D. Clark, Albert D. Edeny, Patrick H. Lau, Dan R. Dukesherer, Lisa McDermott, Michael K. Mao, Gopi Yalamanchili, Jodi L. Moe, Partha Mudipalli, Win Naing, Shaun R. Selness, Christine Seymour, Shekhar Viswanath, John K. Walker
-
Publication number: 20030087422Abstract: Pure bacterial cultures for the production of formylphosphonic acid (FPA) by the oxidation of hydroxymethylphosphonic acid (HMPA) are provided. The cultures can be used to bioremediate HMPA contaminated wastewater or soil, or can be used to produce biogenic FPA for subsequent use. The production of glyphosate from biogenic FPA is described.Type: ApplicationFiled: July 15, 2002Publication date: May 8, 2003Applicant: Monsanto Technology LLC.Inventors: Michael A. Heitkamp, B. Mason Hughes, Shekhar Viswanath